[go: up one dir, main page]

Renzi et al., 2000 - Google Patents

Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine

Renzi et al., 2000

View PDF
Document ID
6805477454823316953
Author
Renzi D
Pellegrini B
Tonelli F
Surrenti C
Calabro A
Publication year
Publication venue
The American journal of pathology

External Links

Snippet

Increasing evidence suggests that tachykinins are involved in the control of pathophysiological states, such as inflammation. The precise localization of tachykinin receptors is of paramount importance in the search for their possible physiological and …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Similar Documents

Publication Publication Date Title
Renzi et al. Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine
Tokunaga et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c‐erbB‐2 in human gastric cancer
Ferns et al. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF
Dong et al. Islet cell and extrapancreatic expression of the LIM domain homeobox gene isl-1
US7807384B2 (en) Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
Dignass et al. Acute epithelial injury in the rat small intestine in vivo is associated with expanded expression of transforming growth factor alpha and beta.
US20100209502A1 (en) Treatments Which Alleviate Functional Glycosylated Leptin Transport Factor for Controlling Weight and Obesity
US20160175401A1 (en) Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
Dardenne et al. Thymic dysfunction in the mutant diabetic (db/db) mouse.
Preiksaitis et al. Pharmacological and molecular characterization of muscarinic receptor subtypes in human esophageal smooth muscle
Cai et al. Keratinocyte growth factor up-regulates Interleukin-7 expression following intestinal ischemia/reperfusion in vitro and in vivo
US20220288054A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
Kakugawa et al. Expression of endothelin‐1 in pancreatic tissue of patients with chronic pancreatitis
US20050239095A1 (en) Use of Pin1 inhibitors for treatment of cancer
WO2006047312A2 (en) COMPOSITIONS AND METHODS FOR MODULATING PGC-1β TO TREAT LIPID-RELATED DISEASES AND DISORDERS
Phares et al. Immunocytological and biochemical localization and biological activity of the newly sequenced cerebral peptide 2 inAplysia
Funk et al. Endotoxin induces parathyroid hormone-related protein gene expression in splenic stromal and smooth muscle cells, not in splenic lymphocytes
Calabro et al. Expression of epidermal growth factor, transforming growth factor-α and their receptor in the human oesophagus
Schindler et al. Field-specific changes in hippocampal opioid mRNA, peptides, and receptors due to prenatal morphine exposure in adult male rats
CN108144060A (en) One kind treats the drug and its screening technique for the disease that monocyte chemoattractant protein-1 participates in by regulating and controlling YB-1 phosphorylations
US20240118284A1 (en) Compositions and methods for detecting plxdc1 and plxcd2 in human tissues
Sickinger et al. Evaluation of differences between breeds for substance P, vasoactive intestinal polypeptide, and neurofilament 200 in the abomasal wall of cattle
Peptidergic Gene and Protein Expression of NK₁ and NK2 Receptors in Crohn's Disease and
WO2002043575A2 (en) Zinc alpha-2-glycoprotein as indicator of cancer
Grinman et al. Cancer-Associated Hypercalcemia Signals Through the Hindbrain to cause Anorexia